The EXLIBRIS clinical trial in non-small-cell lung cancer received approval from the DSMB to continue without modifications, showing the good safety and tolerance profile of Exeliom’s lead candidate EXL01. This was the first time a DSMB oversaw the administration of EXL01 in cancer patients.

The EXLIBRIS study evaluates EXL01 as an advanced line treatment, in combination with nivolumab, for patients who are refractory to this immunotherapy.

‍